冯国伟, 李宏蕾, 朱大帅, 张艳辉, 宋鸽, 张振庭, 陈明, 杜君, 姚欣. 趋化因子CXCL5在肾癌中的表达及临床意义[J]. 中国肿瘤临床, 2018, 45(16): 838-843. DOI: 10.3969/j.issn.1000-8179.2018.16.636
引用本文: 冯国伟, 李宏蕾, 朱大帅, 张艳辉, 宋鸽, 张振庭, 陈明, 杜君, 姚欣. 趋化因子CXCL5在肾癌中的表达及临床意义[J]. 中国肿瘤临床, 2018, 45(16): 838-843. DOI: 10.3969/j.issn.1000-8179.2018.16.636
shu
Feng Guowei, Li Honglei, Zhu Dashuai, Zhang Yanhui, Song Ge, Zhang Zhenting, Chen Ming, Du Jun, Yao Xin. Expression and clinical significance of CXC-chemokine ligand 5 in renal cell carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(16): 838-843. DOI: 10.3969/j.issn.1000-8179.2018.16.636
Citation: Feng Guowei, Li Honglei, Zhu Dashuai, Zhang Yanhui, Song Ge, Zhang Zhenting, Chen Ming, Du Jun, Yao Xin. Expression and clinical significance of CXC-chemokine ligand 5 in renal cell carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(16): 838-843. DOI: 10.3969/j.issn.1000-8179.2018.16.636
shu

趋化因子CXCL5在肾癌中的表达及临床意义

Expression and clinical significance of CXC-chemokine ligand 5 in renal cell carcinoma

    摘要
  • 摘要:
      目的  明确趋化因子配体5（CXC-chemokine ligand 5，CXCL5）在肾癌中的表达情况，探讨其与临床病理特征的关系以及在肿瘤预后评估中的意义。
      方法  通过检索CbioPortal数据库，分析CXCL5表达与肾癌进展和预后的关系。收集2012年11月至2014年6月天津医科大学肿瘤医院收治的105例肾癌患者的临床病理资料，62例组织标本中CXCL5表达患者作为试验组，选择正常肾脏和癌旁组织标本各20例作为对照组，采用免疫组织化学染色和实时定量RT-PCR法评价。根据CXCL5表达水平将患者分为高、中、低表达组，分析各组的表达情况与临床病理特征之间的关系，利用Kaplan-Meier生存分析评价CXCL5表达与患者术后生存率的关系。
      结果  数据库中的结果显示，CXCL5突变患者的总生存期与无病生存期明显缩短（P < 0.05），疾病复发风险明显增加（P < 0.05）；而且，CXCL5 mRNA表达水平与肿瘤转移、分期、阳性淋巴结数量、患者总生存状态均有一定相关性。免疫组织化学法结果显示，肾癌组织中CXCL5的表达明显高于正常肾脏组织和癌旁组织（P < 0.05）；亚组分析显示，CXCL5的表达水平与临床分期、Fuhrman分级呈正相关（P < 0.05）。此外，表达CXCL5的肾癌患者5年生存率（65%）明显低于不表达CXCL5的患者（79%），两者比较差异具有统计学意义（P < 0.05）。
      结论  CXCL5在肾癌中高表达，其表达水平与临床分期和病理分级呈正相关，且与不良预后相关。因此，CXCL5有望成为判断肾癌预后的预测指标和新的治疗靶点。

     

    Abstract:
      Objective  To investigate the expression of C-X-C motif chemokine ligand 5 (CXCL5) in renal cell carcinoma (RCC) and explore the association of CXCL5 with chinicopathological characteristics, as well as its predictive role in prognosis.
      Methods  We analyzed the relationship of CXCL5 expression with disease progression and prognosis based on the refining results from the CbioPortal database. Next, we collected clinical and pathological information from 105 patients with RCC in the Tianjin Medical University Cancer Institute and Hospital from November 2012 to June 2014. Of these, 62 cases expressing CXCL5 served as the experimental group, while samples from normal renal tissue and adjacent renal tissue (n=20 for each) were regarded as the control group. The expression of CXCL5 in these specimens was evaluated using immunohistochemistry and real-time RT-PCR. Patients were sub-grouped based on the expression level of CXCL5 (as low, intermediate, and high expression), and the association of CXCL5 expression with clinicopathological features was delineated. Moreover, Kaplan-Meier analysis was carried out to examine the relationship of CXCL5 expression with the survival rate.
      Results  The data from CbioPortal demonstrated that patients with a CXCL5 mutation had markedly reduced overall survival and disease-free survival (P < 0.05) as well as an increased risk of recurrence (P < 0.05). Additionally, mRNA expression of CXCL5 is associated with cancer metastasis, cancer stage, the number of positive lymph nodes, and the overall survival status of patients. Immunohistochemistry results showed that CXCL5 expression is significantly higher in RCC tissue than in normal renal tissue and adjacent renal tissue (P < 0.05). Sub-group analysis revealed that the expression level of CXCL5 was positively correlated with clinical staging and Fuhrman grading (P < 0.05). Furthermore, the 5-year survival rate was significantly lower in CXCL5 positive patients (65%) than that in CXCL5 negative patients (79%) (P < 0.05).
      Conclusions  CXCL5 is overexpressed in RCC and its expression level is positively associated with clinical staging and pathological grading. Moreover, overexpressed CXCL5 is correlated with poor prognosis. Thus, CXCL5 could serve as a promising predictive candidate and novel therapeutic target for RCC.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回